{"name":"Innovent Biologics","slug":"innovent","ticker":"1801.HK","exchange":"HKEX","domain":"innoventbio.com","description":"Innovent Biologics, Inc. is a publicly listed Chinese biopharmaceutical company that is headquartered in Suzhou, Jiangsu.","hq":"Suzhou, Jiangsu, China","founded":2011,"employees":"7502","ceo":"Michael Yu (De-Chao Yu)","sector":"Immuno-Oncology / Bispecifics / Metabolic","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":86.7,"stockChange":-0.35,"stockChangePercent":-0.4,"marketCap":"$22.2B","metrics":{"revenue":1922082697.2525978,"revenueGrowth":29.6,"grossMargin":76.7,"rdSpend":0,"netIncome":119904648.53099583,"cash":2686982708.038062,"dividendYield":0,"peRatio":160.6,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2028-06-01","label":"Tyvyt patent cliff ($1.4B at risk)","drug":"Tyvyt","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":18,"colorKey":"oncology","drugs":[{"name":"sintilimab,oxaliplatin,S-1","genericName":"sintilimab,oxaliplatin,S-1","slug":"sintilimab-oxaliplatin-s-1","indication":"Other","status":"phase_2"},{"name":"Biological: IBI322","genericName":"Biological: IBI322","slug":"biological-ibi322","indication":"Other","status":"phase_1"},{"name":"IBI318","genericName":"IBI318","slug":"ibi318","indication":"Other","status":"phase_2"},{"name":"IBI362 lyophilized powder","genericName":"IBI362 lyophilized powder","slug":"ibi362-lyophilized-powder","indication":"Other","status":"phase_1"},{"name":"Placebo2","genericName":"Placebo2","slug":"placebo2","indication":"Other","status":"phase_3"},{"name":"[14C] IBI351","genericName":"[14C] IBI351","slug":"14c-ibi351","indication":"Other","status":"phase_1"},{"name":"dose-4 group","genericName":"dose-4 group","slug":"dose-4-group","indication":"Other","status":"phase_1"},{"name":"IBI128","genericName":"IBI128","slug":"ibi128","indication":"Other","status":"phase_2"},{"name":"IBI3009","genericName":"IBI3009","slug":"ibi3009","indication":"Other","status":"phase_1"},{"name":"IBI308 200mg","genericName":"IBI308 200mg","slug":"ibi308-200mg","indication":"Other","status":"phase_1"},{"name":"IBI308\\cisplatin\\gemcitabine","genericName":"IBI308\\cisplatin\\gemcitabine","slug":"ibi308-cisplatin-gemcitabine","indication":"Other","status":"phase_1"},{"name":"IBI315","genericName":"IBI315","slug":"ibi315","indication":"Other","status":"phase_1"},{"name":"IBI356","genericName":"IBI356","slug":"ibi356","indication":"Other","status":"phase_2"},{"name":"Intensive treatment","genericName":"Intensive treatment","slug":"intensive-treatment","indication":"Other","status":"marketed"},{"name":"Placebo SC Q4W","genericName":"Placebo SC Q4W","slug":"placebo-sc-q4w","indication":"Other","status":"phase_3"},{"name":"Placebo1","genericName":"Placebo1","slug":"placebo1","indication":"Other","status":"phase_3"},{"name":"bevacizumab with old manufacturing process.","genericName":"bevacizumab with old manufacturing process.","slug":"bevacizumab-with-old-manufacturing-process","indication":"Other","status":"phase_1"},{"name":"regular treatment","genericName":"regular treatment","slug":"regular-treatment","indication":"Other","status":"marketed"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":16,"colorKey":"immunology","drugs":[{"name":"IBI305","genericName":"IBI305","slug":"ibi305","indication":"Non-small cell lung cancer","status":"phase_3"},{"name":"IBI308","genericName":"IBI308","slug":"ibi308","indication":"Non-small cell lung cancer","status":"phase_3"},{"name":"IBI362","genericName":"IBI362","slug":"ibi362","indication":"Non-small cell lung cancer","status":"phase_3"},{"name":"IBI303","genericName":"IBI303","slug":"ibi303","indication":"Non-small cell lung cancer","status":"phase_3"},{"name":"IBI306","genericName":"IBI306","slug":"ibi306","indication":"Non-small cell lung cancer","status":"phase_3"},{"name":"IBI343","genericName":"IBI343","slug":"ibi343","indication":"Non-small cell lung cancer","status":"phase_3"},{"name":"IBI354","genericName":"IBI354","slug":"ibi354","indication":"Non-small cell lung cancer","status":"phase_3"},{"name":"IBI301 plus CHOP","genericName":"IBI301 plus CHOP","slug":"ibi301-plus-chop","indication":"Lymphoma (in combination with CHOP chemotherapy)","status":"phase_3"},{"name":"IBI310","genericName":"IBI310","slug":"ibi310","indication":"Advanced or metastatic solid tumors (Phase 3 development)","status":"phase_3"},{"name":"IBI310&Sintilimab","genericName":"IBI310&Sintilimab","slug":"ibi310-sintilimab","indication":"Advanced or metastatic solid tumors (Phase 3 development)","status":"phase_3"},{"name":"IBI343,Gemcitabine, Albumin-bound Paclitaxel","genericName":"IBI343,Gemcitabine, Albumin-bound Paclitaxel","slug":"ibi343-gemcitabine-albumin-bound-paclitaxel","indication":"Breast cancer","status":"phase_2"},{"name":"IBI343,sintilimab,oxaliplatin,S-1","genericName":"IBI343,sintilimab,oxaliplatin,S-1","slug":"ibi343-sintilimab-oxaliplatin-s-1","indication":"Non-small cell lung cancer","status":"phase_2"},{"name":"IBI363","genericName":"IBI363","slug":"ibi363","indication":"Advanced or metastatic solid tumors (Phase 3 development)","status":"phase_3"},{"name":"dose 1 IBI302","genericName":"dose 1 IBI302","slug":"dose-1-ibi302","indication":"Non-small cell lung cancer, PD-L1 positive","status":"phase_3"},{"name":"paclitaxel/Gemcitabine/Liposomal doxorubicin","genericName":"paclitaxel/Gemcitabine/Liposomal doxorubicin","slug":"paclitaxel-gemcitabine-liposomal-doxorubicin","indication":"Metastatic breast cancer, Metastatic pancreatic cancer, Metastatic ovarian cancer","status":"phase_3"},{"name":"placebo /IBI112","genericName":"placebo /IBI112","slug":"placebo-ibi112","indication":"Non-small cell lung cancer, PD-L1 positive","status":"phase_3"}]},{"name":"Ophthalmology","slug":"ophthalmology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"cardiovascular","drugs":[{"name":"Teprotumumab N01","genericName":"Teprotumumab N01","slug":"teprotumumab-n01","indication":"Thyroid eye disease (TED) / Graves' ophthalmopathy","status":"marketed"}]}],"pipeline":[{"name":"sintilimab,oxaliplatin,S-1","genericName":"sintilimab,oxaliplatin,S-1","slug":"sintilimab-oxaliplatin-s-1","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Biological: IBI322","genericName":"Biological: IBI322","slug":"biological-ibi322","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"IBI305","genericName":"IBI305","slug":"ibi305","phase":"phase_3","mechanism":"IBI305 is a PD-L1 inhibitor that blocks the interaction between PD-L1 on tumor cells and PD-1/B7.1 on immune cells, thereby restoring anti-tumor immune responses.","indications":["Non-small cell lung cancer","Gastric cancer","Esophageal cancer"],"catalyst":""},{"name":"IBI308","genericName":"IBI308","slug":"ibi308","phase":"phase_3","mechanism":"IBI308 is a PD-1 inhibitor that blocks the interaction between PD-1 on T cells and PD-L1/PD-L2 on tumor cells, thereby restoring anti-tumor immune responses.","indications":["Non-small cell lung cancer","Gastric cancer","Esophageal cancer"],"catalyst":""},{"name":"IBI362","genericName":"IBI362","slug":"ibi362","phase":"phase_3","mechanism":"IBI362 is a bispecific antibody that simultaneously engages PD-1 on immune cells and TGF-β in the tumor microenvironment to enhance anti-tumor immunity.","indications":["Non-small cell lung cancer","Other solid tumors (in development)"],"catalyst":""},{"name":"IBI303","genericName":"IBI303","slug":"ibi303","phase":"phase_3","mechanism":"IBI303 is a PD-1 inhibitor that blocks the interaction between PD-1 on T cells and PD-L1/PD-L2 on tumor cells, thereby restoring anti-tumor immune responses.","indications":["Non-small cell lung cancer","Gastric cancer","Esophageal cancer"],"catalyst":""},{"name":"IBI306","genericName":"IBI306","slug":"ibi306","phase":"phase_3","mechanism":"IBI306 is a PD-1 inhibitor that blocks the interaction between PD-1 on T cells and PD-L1/PD-L2 on tumor cells, thereby restoring anti-tumor immune responses.","indications":["Non-small cell lung cancer","Gastric cancer","Esophageal cancer"],"catalyst":""},{"name":"IBI318","genericName":"IBI318","slug":"ibi318","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"IBI343","genericName":"IBI343","slug":"ibi343","phase":"phase_3","mechanism":"IBI343 is a bispecific antibody that simultaneously engages PD-1 on immune cells and TGF-β in the tumor microenvironment to enhance anti-tumor immunity.","indications":["Non-small cell lung cancer","Other solid tumors (in development)"],"catalyst":""},{"name":"IBI354","genericName":"IBI354","slug":"ibi354","phase":"phase_3","mechanism":"IBI354 is a bispecific antibody that simultaneously engages PD-1 on immune cells and TGF-β in the tumor microenvironment to enhance anti-tumor immunity.","indications":["Non-small cell lung cancer","Other solid tumors (in development)"],"catalyst":""},{"name":"IBI362 lyophilized powder","genericName":"IBI362 lyophilized powder","slug":"ibi362-lyophilized-powder","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Placebo2","genericName":"Placebo2","slug":"placebo2","phase":"phase_3","mechanism":"Placebo2 does not have an active pharmacological mechanism; it is designed as a control in clinical trials.","indications":[],"catalyst":""},{"name":"[14C] IBI351","genericName":"[14C] IBI351","slug":"14c-ibi351","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"dose-4 group","genericName":"dose-4 group","slug":"dose-4-group","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"IBI128","genericName":"IBI128","slug":"ibi128","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"IBI3009","genericName":"IBI3009","slug":"ibi3009","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"IBI301 plus CHOP","genericName":"IBI301 plus CHOP","slug":"ibi301-plus-chop","phase":"phase_3","mechanism":"IBI301 is a PD-L1 inhibitor combined with CHOP chemotherapy to enhance anti-tumor immune response while providing cytotoxic chemotherapy.","indications":["Lymphoma (in combination with CHOP chemotherapy)"],"catalyst":""},{"name":"IBI308 200mg","genericName":"IBI308 200mg","slug":"ibi308-200mg","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"IBI308\\cisplatin\\gemcitabine","genericName":"IBI308\\cisplatin\\gemcitabine","slug":"ibi308-cisplatin-gemcitabine","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"IBI310","genericName":"IBI310","slug":"ibi310","phase":"phase_3","mechanism":"IBI310 is a bispecific antibody that simultaneously engages PD-1 on T cells and TIM-3 on tumor-infiltrating lymphocytes to enhance anti-tumor immune responses.","indications":["Advanced or metastatic solid tumors (Phase 3 development)"],"catalyst":""},{"name":"IBI310&Sintilimab","genericName":"IBI310&Sintilimab","slug":"ibi310-sintilimab","phase":"phase_3","mechanism":"IBI310 is a bispecific antibody that simultaneously blocks CTLA-4 and TIM-3 checkpoints to enhance anti-tumor immunity, while Sintilimab is a PD-1 inhibitor that releases PD-1-mediated immune suppression.","indications":["Advanced or metastatic solid tumors (Phase 3 development)","Non-small cell lung cancer"],"catalyst":""},{"name":"IBI315","genericName":"IBI315","slug":"ibi315","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"IBI343,Gemcitabine, Albumin-bound Paclitaxel","genericName":"IBI343,Gemcitabine, Albumin-bound Paclitaxel","slug":"ibi343-gemcitabine-albumin-bound-paclitaxel","phase":"phase_2","mechanism":"Gemcitabine is a nucleoside analog that inhibits DNA synthesis by interfering with DNA polymerase.","indications":["Breast cancer","Ovarian cancer","Pancreatic cancer","Non-small cell lung cancer"],"catalyst":""},{"name":"IBI343,sintilimab,oxaliplatin,S-1","genericName":"IBI343,sintilimab,oxaliplatin,S-1","slug":"ibi343-sintilimab-oxaliplatin-s-1","phase":"phase_2","mechanism":"Programmed death-ligand 1 inhibitor","indications":["Non-small cell lung cancer","Colorectal cancer"],"catalyst":""},{"name":"IBI356","genericName":"IBI356","slug":"ibi356","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"IBI363","genericName":"IBI363","slug":"ibi363","phase":"phase_3","mechanism":"IBI363 is a bispecific antibody that simultaneously engages PD-1 on immune cells and TIM-3 on T cells to enhance anti-tumor immune responses.","indications":["Advanced or metastatic solid tumors (Phase 3 development)"],"catalyst":""},{"name":"Intensive treatment","genericName":"Intensive treatment","slug":"intensive-treatment","phase":"marketed","mechanism":"Inhibits programmed death-ligand 1 (PD-L1) to restore T-cell mediated immune response against cancer cells.","indications":[],"catalyst":""},{"name":"Placebo SC Q4W","genericName":"Placebo SC Q4W","slug":"placebo-sc-q4w","phase":"phase_3","mechanism":"This is a placebo control used in clinical trials and does not exert any active pharmacological effect.","indications":[],"catalyst":""},{"name":"Placebo1","genericName":"Placebo1","slug":"placebo1","phase":"phase_3","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Teprotumumab N01","genericName":"Teprotumumab N01","slug":"teprotumumab-n01","phase":"marketed","mechanism":"Teprotumumab is a human monoclonal antibody that inhibits insulin-like growth factor-1 receptor (IGF-1R) signaling to reduce inflammation and fibrosis in thyroid eye disease.","indications":["Thyroid eye disease (TED) / Graves' ophthalmopathy"],"catalyst":""},{"name":"bevacizumab with old manufacturing process.","genericName":"bevacizumab with old manufacturing process.","slug":"bevacizumab-with-old-manufacturing-process","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"dose 1 IBI302","genericName":"dose 1 IBI302","slug":"dose-1-ibi302","phase":"phase_3","mechanism":"IBI302 is an anti-PD-1 monoclonal antibody that works by binding to the PD-1 receptor and blocking its interaction with PD-L1, thereby enhancing T-cell mediated immune response.","indications":["Non-small cell lung cancer, PD-L1 positive","Head and neck squamous cell carcinoma"],"catalyst":""},{"name":"paclitaxel/Gemcitabine/Liposomal doxorubicin","genericName":"paclitaxel/Gemcitabine/Liposomal doxorubicin","slug":"paclitaxel-gemcitabine-liposomal-doxorubicin","phase":"phase_3","mechanism":"Paclitaxel inhibits microtubule dynamics, Gemcitabine is a nucleoside analog that inhibits DNA synthesis, and Liposomal doxorubicin is an anthracycline antibiotic that intercalates DNA.","indications":["Metastatic breast cancer, Metastatic pancreatic cancer, Metastatic ovarian cancer"],"catalyst":""},{"name":"placebo /IBI112","genericName":"placebo /IBI112","slug":"placebo-ibi112","phase":"phase_3","mechanism":"IBI112 is an anti-PD-1 monoclonal antibody.","indications":["Non-small cell lung cancer, PD-L1 positive","Head and neck squamous cell carcinoma"],"catalyst":""},{"name":"regular treatment","genericName":"regular treatment","slug":"regular-treatment","phase":"marketed","mechanism":"Unable to determine specific mechanism without additional drug identifier or name.","indications":[],"catalyst":""}],"recentEvents":[{"date":"2023-06-30","type":"earnings","headline":"Innovent Biologics Reports Strong First-Half 2023 Financial Results","summary":"Innovent Biologics reported strong first-half 2023 financial results, with revenue growth driven by the success of its marketed products, including Tyvyt and Sintilimab.","drugName":"","sentiment":"positive"},{"date":"2022-12-15","type":"deal","headline":"Innovent Biologics Enters into Strategic Collaboration with Lilly","summary":"Innovent Biologics entered into a strategic collaboration with Eli Lilly and Company to develop and commercialize several innovative therapies for the treatment of cancer and other diseases.","drugName":"","sentiment":"positive"},{"date":"2022-09-01","type":"regulatory","headline":"Innovent Biologics Receives NMPA Approval for Sintilimab in Combination with Chemotherapy for the Treatment of NSCLC","summary":"Innovent Biologics received approval from the National Medical Products Administration (NMPA) for Sintilimab in combination with chemotherapy for the treatment of non-small cell lung cancer (NSCLC).","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxQRWY5eHBoRzU1bE90ZFBtM0VMVnlGZXE4Z3pVQm5rX0Qwc3E2aTZzdWpaYTdTWVFTM3hDWjBqWURzTW8yVjVob3cxdDNiRnFzMDNWWC1qZ3JuNi00SDlPd3NrN01OWWxSZnJ0NW9MNklFbi1IMF9XN3lQd2lMY0RwNEtjUjFHU003T2VkNmRRSVMya1JLOFR5dWg0VQ?oc=5","date":"2025-10-30","type":"deal","source":"thebambooworks.com","summary":"So big but so what? Innovent’s license deal fails to excite investors - thebambooworks.com","headline":"So big but so what? Innovent’s license deal fails to excite investors","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxNWkdhZ0ZTZkZ5M3JQV2JyMlIxNHVTbHdWVHkxSEdIdk41LXB2aEZ6RHFsLUU3SlJxR3dQY2M2bFgzRFF3NWo3S2lRaDh4NTdUTzd1aXIzTzV3S2ZLeHp6aWEwajZYb1AwMFZOd01fVDVhSG5FcjFTLXMxZUJWRWVDLTNBVVFoTldSMEgzSHlRd0s1RXpVNWFCMFB6OA?oc=5","date":"2025-10-28","type":"pipeline","source":"The Pharma Letter","summary":"Innovent hands Lilly another win over Novo Nordisk - The Pharma Letter","headline":"Innovent hands Lilly another win over Novo Nordisk","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikgFBVV95cUxPNmtVNGk3V1JDdWctcXlGelEwSXJkMWptVVdpLVA4ZGs2ZUpyQzlnSTFLLUhHRTg1MlNvbmYxNExRRlVDUEN1eGxPRHFZcGJ3elNVQmk2QzBtak1hbnFOazA0LU5tMG9rZDVZVUhLdFhCN24zUGtQWGJCN0RYWE8tX01WUVpycHMyQkkyTi04YVlMZw?oc=5","date":"2025-10-23","type":"deal","source":"thebambooworks.com","summary":"Armed with AstraZeneca deal, Eccogene files for Hong Kong IPO - thebambooworks.com","headline":"Armed with AstraZeneca deal, Eccogene files for Hong Kong IPO","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwgFBVV95cUxNZW84WG1JNjVsbTdaMzRSbjJxcUVabWZFbWtmYU5xSmkzajdSc0JHM2xPaTh1UXkwZGVvQkJTWXYtSEVtZ3ZxSjlyZnQ5S29NMDljbUhnMGhwRVZlZ040R1NYeHd3aHJjVVRKakF2dXZBQ3ZNbmJ4aGFJeGQ4OS00SHBqS2dMRGg0WW5XZkRBRXk1aDZrTXJYY29wWTVCWk8tT0hWbUNhRjJlVFVHSE14UkJsT19OR0dPZDc4T3pBQjNWUQ?oc=5","date":"2025-10-22","type":"deal","source":"Yicai Global","summary":"China's Innovent Licenses Cancer Drugs to Takeda Pharma for Up to USD11.4 Billion - Yicai Global","headline":"China's Innovent Licenses Cancer Drugs to Takeda Pharma for Up to USD11.4 Billion","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0gFBVV95cUxQaHdRa0NTVjJGSTJNOUU5Z1F6VGlXNjRRWWtiTEQxbWtuOUFKU1lQQ05neW0tMHZBeGcxZXpmaXdkSWdkWVEwTzYwRGNrMTB6MV84aWpNZ3E2NDBEZlZvZ1pGMjdKYk5oWElyTGVWZUpwZ2Q5M2lJVEMwU3hRQmhiMEpQTFlwN1hEdXhTckNUVWh5NjhxSUZudjVaeDFnMk0zTXBKOW01eUVUc3gxR0wyczJDekY5aUs2YU9YT2M0blA5YkI3NUZaLUpmUWdHUlNyWGc?oc=5","date":"2025-09-23","type":"pipeline","source":"Reuters","summary":"Innovent's weight-loss drug highlights China challenge for Novo, Lilly - Reuters","headline":"Innovent's weight-loss drug highlights China challenge for Novo, Lilly","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiyAFBVV95cUxQamRTVUZpdnVnVndvTlZ4MDZkTlhjelpRNlptaGNQd0dCdmdFUXFFZXpfbjRJQ1lDVTZnSEpTa3REZUlLTWozOEJpd0luVm5FeXlnb240eVZuV0ltYi1wd2RHclpEcHZYQWFlRjlvNHRRMnVtNHB5b1U3Ty0zRWhxdVlLNUdCS3NnelBrNXdtYzFzZzRBWjFfZWd1YU41Q2YzQnRINTVVWmhhUW9ueUJPRU9BYzdZbi1lUnhpd3hPRF8xZHlQOWZITg?oc=5","date":"2025-04-07","type":"regulatory","source":"Yicai Global","summary":"As Chinese Pharma Stocks Dive, Insiders Say Novel Drug Deals Remain Untouched by US Tariff Hike - Yicai Global","headline":"As Chinese Pharma Stocks Dive, Insiders Say Novel Drug Deals Remain Untouched by US Tariff Hike","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiowFBVV95cUxPaG50UWdteEdnT3hxXzNWWUdJYXVKNGpSNGV6bzdLd1FtSW9VM19qOGhYWTA3UGk5cW1hNERFTDNsLTF3ODNjeVh1NC1KYjkzS1ZNcmt5czdQOFJoVXlINDhka0lpTlN5YXI4ZTJ4TjdvQVJSSXJpQlpSSDEzUzdJSWRfZ2VoeDZiN2N0RTdBdjJWMU5Yd3gtcnJEZjZ5Y29RWktF?oc=5","date":"2024-09-27","type":"earnings","source":"thebambooworks.com","summary":"Facing revenue crisis, Ascletis Pharma tries to bulk up with obesity drugs - thebambooworks.com","headline":"Facing revenue crisis, Ascletis Pharma tries to bulk up with obesity drugs","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikwFBVV95cUxNRFc0WVd3TnY0RXFjQmEzWnNOejNWOXV5MXVIYTdRc0NuS1R3ZHItVlAwYmR2UmhWcnB6RTZ5aVNPa0d2bk8yZ2lOWUdZMGNyU2tmMHVkWTVVc1Rvcm8yWnpPOWlQa1lwNldnNE5SbHV3T0s5WUxJc0owWHBBX0l1OHF0Q2FhOHpxTVlxZndVdVVuRDA?oc=5","date":"2024-09-19","type":"pipeline","source":"thebambooworks.com","summary":"CSPC Pharma taps R&D superstar in quest for new breakout drugs - thebambooworks.com","headline":"CSPC Pharma taps R&D superstar in quest for new breakout drugs","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijwFBVV95cUxPUHRFcWJ1QkNzUDNPUGVjbkNkbng5Ty1oSG1adl9jRWpiZTBHR0tiVzJrTEhySFZReTAyTHc5OXg2NU5NTmFzaEt0RWUwZkxmYlVVWlpOVVhENFNrWTVxT1Fnck9aNDJzU2l2ZmRjZnltaExBaWlEenZwTG5zRDQxVGwyZnE3SFJpZTBRNWd5VQ?oc=5","date":"2024-06-27","type":"deal","source":"thebambooworks.com","summary":"Ascentage Pharma soars on deal with cancer drug competitor - thebambooworks.com","headline":"Ascentage Pharma soars on deal with cancer drug competitor","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiVkFVX3lxTE52Z3d1SGRYM0lGUkJ5SjNjS0IxMFFiM0t4MEdDSXFka3RWTDBGMFk0OVJ5MW56bEVaakp0RXM5N3VEbDJKalZqQ2RqengyUnB6Wk0tWTBR?oc=5","date":"2020-04-19","type":"pipeline","source":"Yahoo Finance Australia","summary":"Akeso, Inc. (9926.HK) stock price, news, quote and history - Yahoo Finance Australia","headline":"Akeso, Inc. (9926.HK) stock price, news, quote and history","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiVkFVX3lxTE5yQXhQZVgyVEFMbzVPQk5LOHVlV01pZko3ZnhDM0ZVX1B3d3dBaXotcWpCbG1kbkxjN2YzejUxaV9ZV1NIdjhIbzNRaU4xeXM5VDNUdVpn?oc=5","date":"2017-06-26","type":"pipeline","source":"Yahoo! Finance Canada","summary":"3SBio Inc. (1530.HK) Stock Price, News, Quote & History - Yahoo! Finance Canada","headline":"3SBio Inc. (1530.HK) Stock Price, News, Quote & History - Yahoo! Finance Canada","sentiment":"neutral"}],"patents":[{"drugName":"Tyvyt","drugSlug":"sintilimab","patentNumber":"","type":"Patent Cliff","expiryDate":"2028-06-01","territory":"US","annualRevenue":1400000000}],"drugCount":35,"phaseCounts":{"phase_2":6,"phase_1":9,"phase_3":17,"marketed":3},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Bristol Myers Squibb","Merck & Co.","AstraZeneca"],"therapeuticFocus":["Immuno-Oncology","Bispecifics","Metabolic Diseases"],"financials":{"source":"yahoo_finance","revenue":1922082743.23571,"revenuePeriod":"2025-12-31","revenueHistory":[{"period":"2025-12-31","value":1922082743.23571},{"period":"2024-12-31","value":1388614530.18176},{"period":"2023-12-31","value":914661581.3439},{"period":"2022-12-31","value":671527349.1926}],"grossProfit":1663277554.8620799,"grossProfitHistory":[{"period":"2025-12-31","value":1663277554.8620799},{"period":"2024-12-31","value":1166037107.31006},{"period":"2023-12-31","value":747196687.07308},{"period":"2022-12-31","value":534316395.1403}],"rdSpend":386761304.17877996,"rdSpendHistory":[{"period":"2025-12-31","value":386761304.17877996},{"period":"2024-12-31","value":395141431.62097996},{"period":"2023-12-31","value":328301146.05412},{"period":"2022-12-31","value":423165485.6594}],"sgaSpend":978598888.18707,"operatingIncome":315531547.35600996,"operatingIncomeHistory":[{"period":"2025-12-31","value":315531547.35600996},{"period":"2024-12-31","value":38042035.09063},{"period":"2023-12-31","value":-134000979.1017},{"period":"2022-12-31","value":-380522781.23645}],"netIncome":119904649.71005,"netIncomeHistory":[{"period":"2025-12-31","value":119904649.71005},{"period":"2024-12-31","value":-13946884.27687},{"period":"2023-12-31","value":-151495637.34601},{"period":"2022-12-31","value":-321184669.9079}],"eps":0.47,"epsHistory":[{"period":"2025-12-31","value":0.47},{"period":"2024-12-31","value":-0.06},{"period":"2023-12-31","value":-0.66},{"period":"2022-12-31","value":-1.46}],"cash":2556293323.02785,"cashHistory":[{"period":"2025-12-31","value":2556293323.02785},{"period":"2024-12-31","value":1106569594.78745},{"period":"2023-12-31","value":404665094.21661},{"period":"2022-12-31","value":149764196.31204998}],"totalAssets":5504390617.495029,"totalLiabilities":2651633263.60492,"totalDebt":414993903.42175,"equity":2852757353.89011,"operatingCashflow":1473966850.35124,"operatingCashflowHistory":[{"period":"2025-12-31","value":1473966850.35124},{"period":"2024-12-31","value":189683875.15248},{"period":"2023-12-31","value":21784499.4237},{"period":"2022-12-31","value":-282796729.80307996}],"capex":-100702131.51498,"capexHistory":[{"period":"2025-12-31","value":-100702131.51498},{"period":"2024-12-31","value":-251346639.13924},{"period":"2023-12-31","value":-203896783.5242},{"period":"2022-12-31","value":-203641813.0621}],"freeCashflow":1373264718.8362598,"dividendsPaid":null,"buybacks":null,"employees":7502,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":86.7,"previousClose":87.05,"fiftyTwoWeekHigh":109.1,"fiftyTwoWeekLow":49.1,"fiftyTwoWeekRange":"49.1 - 109.1","fiftyDayAverage":86.34,"twoHundredDayAverage":88.83,"beta":0.24,"enterpriseValue":19893028952.927845,"forwardPE":32.5,"priceToBook":6.74,"priceToSales":11.53,"enterpriseToRevenue":10.35,"enterpriseToEbitda":103.02,"pegRatio":0,"ebitda":193092511.29660672,"ebitdaMargin":10,"freeCashflow":475768689.8861517,"operatingCashflow":1473966807.9052901,"totalDebt":414993899.8845875,"debtToEquity":14.5,"currentRatio":2.62,"returnOnAssets":1.6,"returnOnEquity":5,"analystRating":"1.4 - Strong Buy","recommendationKey":"strong_buy","numberOfAnalysts":27,"targetMeanPrice":116.42,"targetHighPrice":149.12,"targetLowPrice":83.09,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":6.3,"institutionHeldPercent":55.9,"sharesOutstanding":1734623465,"floatShares":1609973423,"sharesShort":0,"shortRatio":0,"shortPercentOfFloat":0,"epsTrailing":0.54,"epsForward":2.66,"revenuePerShare":7.77,"bookValue":12.86,"officers":[{"age":61,"name":"Dr. De-Chao  Yu Ph.D.","title":"Co-Founder, Chairman & CEO"},{"age":66,"name":"Mr. Hao Xi  Ede","title":"Executive Director & Fund Managing Partner"},{"age":37,"name":"Ms. Qian  Zhang","title":"Chief Commercial Officer, General Manager & Executive Director"},{"age":46,"name":"Ms. Fei  You CPA","title":"Chief Financial Officer"},{"age":null,"name":"Dr. Kaisong  Zhou Ph.D.","title":"Chief Operating Officer"},{"age":null,"name":"Ms. Zhengwei  Song C.F.A.","title":"Director of IR & Financial Strategy"},{"age":null,"name":"Ms. Cong  Ding J.D.","title":"General Counsel"},{"age":null,"name":"Mr. Blake  Salisbury","title":"Senior Vice President"}],"industry":"Biotechnology","irWebsite":"","website":"https://www.innoventbio.com","phone":"86 512 6956 6088"}}